Navigation Links
Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
Date:1/18/2008

LONDON, January 18 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRND) today announced that, at a General Meeting held yesterday, its shareholders approved a 1 for 10 reverse split of each of its Ordinary Shares. The reverse split became effective as of the close of business yesterday, January 17, 2008.

Thomas Lynch, Amarin Chairman and Chief Executive Officer, commented "We are very pleased to report that over 95% of the votes cast by our shareholders approved the one-for-ten reverse stock split. We have made good progress in recent months expanding our management team and broadening our pipeline and look forward to executing on our strategy which we believe will drive shareholder value in 2008."

Under customary Nasdaq practice, with effect from today, January 18, 2008, and for a period of 20 trading days, a "D" will be appended to Amarin's Nasdaq ticker symbol and during that period Amarin's Nasdaq ticker symbol will appear as "AMRND".

Pipeline Update

Through 2007, the Company embarked upon a program of broadening its development pipeline with the objective of having multiple late stage programs with an appropriate balance of portfolio risk.

This was facilitated by the achievement of a number of important milestones. Firstly, the completion of a comprehensive analysis of the 12-month data from the US Phase III trial of Miraxion (AMR101) in Huntington's disease (HD) showing a statistically significant benefit with Miraxion over longer periods of treatment, and the corresponding feedback from the U.S. Food and Drug Administration (FDA).

Amarin also conducted a thorough analysis and re-configuration of its existing pipeline from which the Company's cardiovascular initiative was launch
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
2. Amarin Signs Agreement to Acquire Ester Neurosciences
3. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
4. Amarin Announces Initiation of Cardiovascular Development Strategy
5. Amarin to Present at 4th Annual Bio Investor Forum
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. YM BioSciences provides update on AeroLEF(TM) clinical development program
8. ViroPharma Provides 2008 Outlook
9. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
10. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
11. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Biovista Inc. freut sich, ... 2015 bekanntgeben zu können. Hierbei handelt es sich ... Biovista unterstützt mit seiner Möglichkeit der Analyse ... Krankheiten als denen, für die ein Medikament ursprünglich ... Team bei der Wylder Nation Foundation bei der ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Services Staff members will be attending Pharma Ed Resources upcoming educational seminar ... group of industry leading speakers, this timely conference will provide Updates & Case ...
(Date:9/2/2015)... Diego, CA (PRWEB) , ... September 02, 2015 ... ... troubleshooting faults in manufacturing equipment, to creating professional commercial video content, to analysis ... detailed views of fascinating events that go by too quickly to process with ...
(Date:9/1/2015)... Swecure, ein Biotechnologieunternehmen, ... Entwicklung neuartiger Therapien für Störungen des Immunsystems ... konzentriert, erhält vom US Patent and Trademark ... patentiert wird. Das Medikament basiert auf einem ... und Entzündungen vorbeugt.   Das Medikament, ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... October 5 , - A New Miniaturized PCR ... Price of QuanTyper(TM) Without Loss of Performance, - ... AlphaHelix (Ticker: ALPH) has in a very ... for lower,instrument prices. This was made possible through know-how obtained during,the ...
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... bavituximab in combination with carboplatin and paclitaxel in patients ... reported from the initial cohort of 21 patients in ... patients with locally advanced or metastatic NSCLC achieved an ...
... ... Global packaging specialist,Sepha, says the increased pressure to reduce costs and ... and blister-scanning technologies. While blisterpacks offer pharmaceutical companies a simple ... often makes it difficult to either test for leaks or recover ...
Cached Biology Technology:AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 4Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering 2Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering 3
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... LyondellBasell announced the following schedule and contact information for a teleconference on financial results through the ... , Monday, August 16, 2010 , ... Doug Pike, Vice President, Investor Relations , ... 800-369-1176 , London: 0800-279-9630 , ...
... Georgia Institute of Technology are using funding from the ... as ARPA-E to pursue two different, but related, ... of coal-burning power plants. Power plants ... the United States each year. The researchers will ...
... URBANA A dog,s indiscriminate taste is not always ... gastrointestinal infections and consequent ailments such as diarrhea and ... gastrointestinal diseases such as inflammatory bowel diseases that are ... by intestinal bacteria. Researchers at the University ...
Cached Biology News:Teleconference Alert: LyondellBasell Reviews Second Quarter 2010 Financial Results 2ARPA-E funding supports research on carbon dioxide removal from flue gases 2ARPA-E funding supports research on carbon dioxide removal from flue gases 3ARPA-E funding supports research on carbon dioxide removal from flue gases 4Illinois researchers use pyrosequencing to study canine intestinal bacteria 2
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Biology Products: